Study of Efficacy of PAD-regimen(Bortezomib,Pirarubicin and Dexamethasone) and TAD-regimen(Thalidomide,Pirarubicin and Dexamethasone) in Newly Diagnosed Multiple Myeloma,Influence in Concentration of Bone Metabolites,and the Relations With Different Cytogenetic and Molecular Biological Changes
Multiple myeloma (MM) is a malignant tumor with abnormal proliferation of monoclonal plasma
cells in bone marrow. Bone damage is one of the characteristic clinical manifestations.
Myeloma plasma cells and bone marrow microenvironment are the targets of thalidomide and
bortezomib. The regimens based on them as first-line treatments of MM have greatly improved
efficacy and prolonged the survival of MM patients. But whether the regimens can prevent
and treat bone complications of MM patients or improve the quality of life is not clear. By
evaluating the efficacy of PAD-regimen(Bortezomib,Pirarubicin and Dexamethasone) and
TAD-regimen(Thalidomide,Pirarubicin and Dexamethasone) in MM and the effect of them on bone
lesions, this study can provide evidence of evidence-based medicine for MM treatment.
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
The overall response rate of PAD and TAD in patients with MM assessed by International Myeloma Working Group(IMWG) criteria
every treatment cycle
Jian Hou, PhD
Shanghai Changzheng Hospital
China: Ethics Committee